 Neutropenia
"Neutropenia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A decrease in the number of NEUTROPHILS found in the blood.
| Descriptor ID |
D009503
|
| MeSH Number(s) |
C15.378.553.546.184.564
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Neutropenia".
Below are MeSH descriptors whose meaning is more specific than "Neutropenia".
This graph shows the total number of publications written about "Neutropenia" by people in this website by year, and whether "Neutropenia" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1989 | 1 | 0 | 1 | | 1991 | 1 | 0 | 1 | | 1992 | 1 | 0 | 1 | | 1993 | 1 | 1 | 2 | | 1994 | 1 | 0 | 1 | | 1995 | 4 | 2 | 6 | | 1996 | 0 | 4 | 4 | | 1997 | 2 | 1 | 3 | | 1998 | 0 | 1 | 1 | | 1999 | 0 | 2 | 2 | | 2000 | 0 | 2 | 2 | | 2001 | 2 | 2 | 4 | | 2003 | 1 | 0 | 1 | | 2004 | 1 | 5 | 6 | | 2005 | 2 | 1 | 3 | | 2006 | 0 | 1 | 1 | | 2007 | 2 | 0 | 2 | | 2008 | 1 | 1 | 2 | | 2009 | 0 | 3 | 3 | | 2010 | 1 | 4 | 5 | | 2011 | 1 | 0 | 1 | | 2012 | 1 | 4 | 5 | | 2013 | 1 | 3 | 4 | | 2014 | 1 | 0 | 1 | | 2015 | 3 | 3 | 6 | | 2016 | 2 | 2 | 4 | | 2017 | 0 | 5 | 5 | | 2018 | 0 | 3 | 3 | | 2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Neutropenia" by people in Profiles.
-
Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2019 02 21; 380(8):741-751.
-
Liu SV, Camidge DR, Gettinger SN, Giaccone G, Heist RS, Hodi FS, Ready NE, Zhang W, Wallin J, Funke R, Waterkamp D, Foster P, Iizuka K, Powderly J. Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. Eur J Cancer. 2018 09; 101:114-122.
-
Chastain DB, Wheeler S, Franco-Paredes C, Olubajo B, Hawkins WA. Evaluating guideline adherence regarding empirical vancomycin use in patients with neutropenic fever. Int J Infect Dis. 2018 Apr; 69:88-93.
-
King GT, Eaton KD, Beagle BR, Zopf CJ, Wong GY, Krupka HI, Hua SY, Messersmith WA, El-Khoueiry AB. A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors. Invest New Drugs. 2018 10; 36(5):836-847.
-
Berry SA, Longo N, Diaz GA, McCandless SE, Smith WE, Harding CO, Zori R, Ficicioglu C, Lichter-Konecki U, Robinson B, Vockley J. Safety and efficacy of glycerol phenylbutyrate for management of urea cycle disorders in patients aged 2months to 2years. Mol Genet Metab. 2017 11; 122(3):46-53.
-
Park JJ, Hajj C, Reyngold M, Shi W, Zhang Z, Cuaron JJ, Crane CH, O'Reilly EM, Lowery MA, Yu KH, Goodman KA, Wu AJ. Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. Acta Oncol. 2017 Dec; 56(12):1746-1753.
-
Ocean AJ, Starodub AN, Bardia A, Vahdat LT, Isakoff SJ, Guarino M, Messersmith WA, Picozzi VJ, Mayer IA, Wegener WA, Maliakal P, Govindan SV, Sharkey RM, Goldenberg DM. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics. Cancer. 2017 Oct 01; 123(19):3843-3854.
-
Goodman KA, Julie D, Cercek A, Cambridge L, Woo KM, Zhang Z, Wu AJ, Reidy DL, Segal NH, Stadler ZK, Saltz LB. Capecitabine With Mitomycin Reduces Acute Hematologic Toxicity and Treatment Delays in Patients Undergoing Definitive Chemoradiation Using Intensity Modulated Radiation Therapy for Anal Cancer. Int J Radiat Oncol Biol Phys. 2017 08 01; 98(5):1087-1095.
-
Jimeno A, Sharma MR, Szyldergemajn S, Gore L, Geary D, Diamond JR, Fernandez Teruel C, Soto Matos-Pita A, Iglesias JL, Cullell-Young M, Ratain MJ. Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule. Invest New Drugs. 2017 08; 35(4):471-477.
-
Murphy JL, Fenn N, Pyle L, Heizer H, Hughes S, Nomura Y, Child J, Parker SK. Adverse Events in Pediatric Patients Receiving Long-term Oral and Intravenous Antibiotics. Hosp Pediatr. 2016 Jun; 6(6):330-8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|